Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Toast Inc. Class A Common Stock (TOST) vs 10X Genomics Inc (TXG) Price & Performance

Toast Inc. Class A Common StockTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Toast Inc. Class A Common Stock vs 10X Genomics Inc — how do they compare? Toast Inc. Class A Common Stock trades at $29.65 (market cap $17.85B), while 10X Genomics Inc trades at $71.84 (market cap $9.35B). The key difference: Toast Inc. Class A Common Stock is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Toast Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Toast Inc. Class A Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.

TOSTTXG
Market Cap
$17.85B$9.35B
Volume
6,311,7184,039,449
Sector
TechnologyHealth
52-Week High
$39.02$97.74
52-Week Low
$22.33$11.83
Typical Hold Time
0 Days91 Days
Enterprise Value
$16.10B$8.88B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Toast Inc. Class A Common Stock

Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.

The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.

10X Genomics Inc

TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.

The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TOST
100% Buy0% Sell
Avg holding period · 0 Days
TXG
17% Buy83% Sell
Avg holding period · 91 Days

Top news

Latest headlines on both assets

About Toast Inc. Class A Common Stock

Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.

Read more on TOST →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →